What We're Reading: Page 220
Industry reads hand-picked by our editors
May 13, 2019
-
The Wall Street Journal
How a Chinese Scientist Broke the Rules to Create the First Gene-Edited Babies
-
Reuters
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
-
BioCentury
White House, Congress considering killing Part D rebate rule, creating spending cap
-
MIT Technology Review
How biotech went from "no way" to payday in the cannabis business
May 10, 2019
-
BioCentury
White House, Pelosi discussing Part D deal
-
Associated Press
Trump backs Fla. plan to import lower-cost meds from abroad
-
The Wall Street Journal
Microbiome startup seeks to reassure investors on ethics
-
STAT
How Insys undermined an FDA effort to protect the public from dangerous opioids
May 09, 2019
-
Mother Jones
Big pharma has a big role on the federal committee tasked with curbing opioid abuse
-
CNN
Former Purdue Pharma president called addicted people 'victimizers' in emails
-
Bloomberg
Botox competitor aims to take market share as Allergan stumbles
-
The New York Times
Robert Pear, Authoritative Times Reporter on Health Care, Dies at 69
May 08, 2019
May 07, 2019
-
The New Yorker
The Birth-Tissue Profiteers
-
The Wall Street Journal
Making monkeys out of the Sohn investing gurus
-
Axios
How to save $80 billion a year on prescription drugs
-
Kaiser Health News
Meth vs. opioids: America has two drug epidemics, but focuses on one
May 06, 2019
-
C&EN
Stanley Crooke on finally making sense out of antisense
-
STAT
Scientists see hope in rare disease drug Wall Street has doubted
-
The Wall Street Journal
Want David Solomon's Take on Something? Buy a Goldman Share and Show Up
-
The New York Times
80,000 Deaths. 2 Million Injuries. It’s Time for a Reckoning on Medical Devices.
May 03, 2019
-
MIT Technology Review
The search for the kryptonite that can stop CRISPR
-
New England Journal of Medicine
Pharmaceutical Protections in U.S. Trade Deals — What Do Americans Get in Return?
-
South China Morning Post
As biotechnology firms become the darlings of Hong Kong's IPO market, their executives get outsized pay packets. Here’s why
Previous
